Subject(s)
COVID-19 , Cholecystitis, Acute , Gallbladder , SARS-CoV-2/isolation & purification , Aged, 80 and over , COVID-19/diagnosis , COVID-19/epidemiology , COVID-19/physiopathology , COVID-19/therapy , Cholecystectomy/methods , Cholecystitis, Acute/blood , Cholecystitis, Acute/physiopathology , Cholecystitis, Acute/therapy , Cholecystitis, Acute/virology , Clinical Deterioration , Comorbidity , Diagnosis, Differential , Fatal Outcome , Female , Gallbladder/diagnostic imaging , Gallbladder/surgery , Gallbladder/virology , Humans , Liver Function Tests/methods , Male , Noncommunicable Diseases/epidemiology , Patient Care Management/methods , RNA, Viral/isolation & purification , Ultrasonography/methodsABSTRACT
Following the spread of the infection from the new SARS-CoV2 coronavirus in March 2020, several surgical societies have released their recommendations to manage the implications of the COVID-19 pandemic for the daily clinical practice. The recommendations on emergency surgery have fueled a debate among surgeons on an international level.We maintain that laparoscopic cholecystectomy remains the treatment of choice for acute cholecystitis, even in the COVID-19 era. Moreover, since laparoscopic cholecystectomy is not more likely to spread the COVID-19 infection than open cholecystectomy, it must be organized in such a way as to be carried out safely even in the present situation, to guarantee the patient with the best outcomes that minimally invasive surgery has shown to have.